Abstract
Purpose
The aim of this retrospective study was to comparatively investigate the expression of the three drug-resistance genes P-glycoprotein (P-gp), multidrug-resistance protein 1 (MRP1), and lung resistance protein (LRP), in non-small cell lung cancer (NSCLC) tissues, and to assess possible associations with clinicopathologic features.
Methods
Tumor specimens from 126 patients were analyzed by immunohistochemistry and, in selected cases, by reverse transcriptase polymerase chain reaction (RT-PCR), and data were statistically analyzed by SPSS.
Results
The mean expression levels of tumor tissues in the case of P-gp and LRP did not exceed the one of normal epithelia, while MRP1 was significantly enhanced in NSCLC. A weak association was observed between higher grading and P-glycoprotein expression ( p <0.08) as well as lower grading and MRP1 expression in the case of adenocarcinoma ( p <0.05). MRP1 levels were highest in TNM stage I and declined with advanced stage ( p <0.03). A significant association was found between high MRP1 levels and longer overall survival ( N =115, p <0.04), which was highly significant in the patient group never treated with chemotherapy ( N =77; p <0.007). P-gp expression was enhanced in those patients who had received chemotherapy before surgery ( p <0.05).
Conclusions
Our data point towards a major role of MRP1 in the intrinsic treatment resistance of NSCLC and suggest, in addition, a significant activation of P-gp expression during chemotherapy.
Similar content being viewed by others
References
Abe Y, Nakamura M, Ota E, Ozeki Y, Tamai S, Inoue H, Ueyama Y, Ogata T, Tamaoki N (1994) Expression of the multidrug resistance gene (MDR1) in non-small cell lung cancer. Jpn J Cancer Res 85:536–541
Abe Y, Ohnishi Y, Yoshimura M, Ota E, Ozeki Y, Oshika Y, Tokunaga T, Yamazaki H, Ueyema Y, Ogata T et al. (1996) P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cells in vivo. Br J Cancer 74:1929–1934
Berger W, Elbling L, Hauptmann E, Micksche M (1997) Expression of the multidrug resistance-associated protein (MRP) and chemoresistance of human non-small-cell lung cancer cells. Int J Cancer 73:84–93
Berger W, Elbling L, Micksche M (2000) Expression of the major vault protein LRP in human non-small-cell lung cancer cells: activation by short-term exposure to antineoplastic drugs. Int J Cancer 88:293–300
Chiou JF, Liang JA, Hsu WH, Wang JJ, Ho ST, Kao A (2003) Comparing the relationship of Taxol-based chemotherapy response with P-glycoprotein and lung resistance-related protein expression in non-small cell lung cancer. Lung 181:267–273
Chuman Y, Sumizawa T, Takebayashi Y, Niwa K, Yamada K, Haraguchi M, Furukawa T, Akiyama S, Aikou T (1996) Expression of the multidrug-resistance-associated protein (MRP) gene in human colorectal, gastric and non-small-cell lung carcinomas. Int J Cancer 66:274–279
Cole SP, Deeley RG (1993) Multidrug resistance-associated protein: sequence correction. Science 260:879
Dingemans AM, van Ark Otte J, van der Valk P, Apolinario RM, Scheper RJ, Postmus PE, Giaccone G (1996) Expression of the human major vault protein LRP in human lung cancer samples and normal lung tissues. Ann Oncol 7:625–630
Doyle LA (1993) Mechanisms of drug resistance in human lung cancer cells. Semin Oncol 20:326–337
Fry WA, Menck HR, Winchester DP (1996) The National Cancer Data Base report on lung cancer. Cancer 77:1947–1955
Giaccone G, van Ark Otte J, Rubio GJ, Gazdar AF, Broxterman HJ, Dingemans AM, Flens MJ, Scheper RJ, Pinedo HM (1996) MRP is frequently expressed in human lung-cancer cell lines, in non-small-cell lung cancer and in normal lungs. Int J Cancer 66:760–767
Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2:48–58
Harada T, Ogura S, Yamazaki K, Kinoshita I, Itoh T, Isobe H, Yamashiro K, Dosaka Akita H, Nishimura M (2003) Predictive value of expression of P53, Bcl-2 and lung resistance-related protein for response to chemotherapy in non-small cell lung cancers. Cancer Sci 94:394–399
Ihde DC, Minna JD (1991) Non-small cell lung cancer. Part II: Treatment. Curr Probl Cancer 15:105–154
Kickhoefer VA, Rajavel KS, Scheffer GL, Dalton WS, Scheper RJ, Rome LH (1998) Vaults are up-regulated in multidrug-resistant cancer cell lines. J Biol Chem 273:8971–8974
Lehne G (2000) P-glycoprotein as a drug target in the treatment of multidrug resistant cancer. Curr Drug Targets 1:85–99
Narasaki F, Oka M, Fukuda M, Nakano R, Ikeda K, Takatani H, Terashi K, Soda H, Yano O, Nakamura T et al (1997) A novel quinoline derivative, MS-209, overcomes drug resistance of human lung cancer cells expressing the multidrug resistance-associated protein (MRP) gene. Cancer Chemother Pharmacol 40:425–432
Nooter K, Bosman FT, Burger H, van Wingerden KE, Flens MJ, Scheper RJ, Oostrum RG, Boersma AW, van der Gaast A, Stoter G (1996) Expression of the multidrug resistance-associated protein (MRP) gene in primary non-small-cell lung cancer. Ann Oncol 7:75–81
Oshika Y, Nakamura M, Tokunaga T, Fukushima Y, Abe Y, Ozeki Y, Yamazaki H, Tamaoki N, Ueyama Y (1998) Multidrug resistance-associated protein and mutant p53 protein expression in non-small cell lung cancer. Mod Pathol 11:1059–1063
Ota E, Abe Y, Oshika Y, Ozeki Y, Iwasaki M, Inoue H, Yamazaki H, Ueyama Y, Takagi K, Ogata T et al (1995) Expression of the multidrug resistance-associated protein (MRP) gene in non-small-cell lung cancer. Br J Cancer 72:550–554
Scagliotti GV, Novello S, Selvaggi G (1999) Multidrug resistance in non-small-cell lung cancer. Ann Oncol 10:83–86
Scheffer GL, Wijngaard PL, Flens MJ, Izquierdo MA, Slovak ML, Pinedo HM, Meijer CJ, Clevers HC, Scheper RJ (1995) The drug resistance-related protein LRP is the human major vault protein. Nat Med 1:578–582
Shtil AA (2001) Signal transduction pathways and transcriptional mechanisms as targets for prevention of emergence of multidrug resistance in human cancer cells. Curr Drug Targets 2:57–77
Spiegl Kreinecker S, Buchroithner J, Elbling L, Steiner E, Wurm G, Bodenteich A, Fischer J, Micksche M, Berger W (2002) Expression and functional activity of the ABC-transporter proteins P-glycoprotein and multidrug-resistance protein 1 in human brain tumor cells and astrocytes. J Neurooncol 57:27–36
Sugawara I, Yamada H, Nakamura H, Sumizawa T, Akiyama S, Masunaga A, Itoyama S (1995) Preferential expression of the multidrug-resistance-associated protein (MRP) in adenocarcinoma of the lung. Int J Cancer 64:322–325
Tan B, Piwnica Worms D, Ratner L (2000) Multidrug resistance transporters and modulation. Curr Opin Oncol 12:450–458
Thomas GA, Barrand MA, Stewart S, Rabbitts PH, Williams ED, Twentyman PR (1994) Expression of the multidrug resistance-associated protein (MRP) gene in human lung tumours and normal tissue as determined by in situ hybridisation. Eur J Cancer 30a:1705–1709
Volm M, Koomagi R, Mattern J, Efferth T (2002) Protein expression profiles indicative for drug resistance of non-small cell lung cancer. Br J Cancer 87:251–257
Wright SR, Boag AH, Valdimarsson G, Hipfner DR, Campling BG, Cole SP, Deeley RG (1998) Immunohistochemical detection of multidrug resistance protein in human lung cancer and normal lung. Clin Cancer Res 4:2279–2289
Yeh JJ, Hsu WH, Wang JJ, Ho ST, Kao A (2003) Predicting chemotherapy response to paclitaxel-based therapy in advanced non-small-cell lung cancer with P-glycoprotein expression. Respiration 70:32–35
Young LC, Campling BG, Cole SP, Deeley RG, Gerlach JH (2001) Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels. Clin Cancer Res 7:1798–1804
Acknowledgements
The work has been supported by the Jubiläumsfonds der Österreichischen Nationalbank Bank, Grant 7258 and the Herzfelder’schen Familienstiftung
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Berger, W., Setinek, U., Hollaus, P. et al. Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: prognostic implications. J Cancer Res Clin Oncol 131, 355–363 (2005). https://doi.org/10.1007/s00432-004-0653-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-004-0653-9